Pablo Lapuerta, the Executive Vice President and Chief Medical Officer of Lexicon Pharmaceuticals, focuses heavily on genetics and drug development. He discusses the messaging that the pharmaceutical industry needs to do in order to help the public understand the extensive processes behind bringing new drugs to market, improvements that could be made in the FDA’s drug approval process, and a novel drug that he and Lexicon have developed to treat Type I diabetes.

Read More